Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma

Por Hirte, Hal W
Publicado em 2013

Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options

Por Elit, Laurie, Hirte, Hal
Publicado em 2013

Induction of hTERT Expression and Telomerase Activity by Estrogens in Human Ovary Epithelium Cells

Por Misiti, Silvia, Nanni, Simona, Fontemaggi, Giulia, Cong, Yu-Sheng, Wen, Jianping, Hirte, Hal W., Piaggio, Giulia, Sacchi, Ada, Pontecorvi, Alfredo, Bacchetti, Silvia, Farsetti, Antonella
Publicado em 2000

Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors

Por Mackay, Helen J., Hirte, Hal, Colgan, Terrence, Covens, Al, MacAlpine, Katrina, Grenci, Pamela, Wang, Lisa, Mason, Jaqueline, Pham, Pnu-An, Tsao, Ming-S, Pan, James, Zwiebel, James, Oza, Amit M.
Publicado em 2010

Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care

Por Miller, Fiona A, Hayeems, Robin Z, Bytautas, Jessica P, Bedard, Philippe L, Ernst, Scott, Hirte, Hal, Hotte, Sebastien, Oza, Amit, Razak, Albiruni, Welch, Stephen, Winquist, Eric, Dancey, Janet, Siu, Lillian L
Publicado em 2014

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

Por Schultheis, Anne M, Lurje, Georg, Rhodes, Katrin E, Zhang, Wu, Yang, Dongyun, Garcia, Agustin A, Morgan, Robert, Gandara, David, Scudder, Sidney, Oza, Amit, Hirte, Hal, Fleming, Gini, Roman, Lynda, Lenz, Heinz-Josef
Publicado em 2008

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

Por Chiu, Joanne W., Hotte, Sebastien J., Kollmannsberger, Christian K., Renouf, Daniel J., Cescon, David W., Hedley, David, Chow, Sue, Moscow, Jeffrey, Chen, Zhuo, Perry, Meghan, Diaz-Padilla, Ivan, Tan, David, Hirte, Hal, McWhirter, Elaine, Chen, Helen, Siu, Lillian L., Bedard, Philippe L.
Publicado no Invest New Drugs (2015)

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

Por Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.
Publicado em 2013

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

Por Richter, Suzanne, Bedard, Philippe L., Chen, Eric Xueyu, Clarke, Blaise A., Tran, Ben, Hotte, Sebastien J., Stathis, Anastasios, Hirte, Hal W., Razak, Albiruni R. A., Reedijk, Michael, Chen, Zhuo, Cohen, Brenda, Zhang, Wen-Jiang, Wang, Lisa, Ivy, S. Percy, Moore, Malcolm J., Oza, Amit M., Siu, Lillian L., McWhirter, Elaine
Publicado em 2013